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ABSTRACT 
Background: Intra-arterial chemotherapy (IAC) for retinoblastoma has been documented as causing 
visual loss and ocular motility problems. A lack of safety data has precluded its acceptance in all 
centres.  
 
 
Methods: Retrospective cohort study of patients with retinoblastoma from 2013 to 2015 who had a 
healthy foveola and relapsed following systemic chemotherapy. All required IAC. The correlation of 
complications with doses of melphalan +/- topotecan used and putative catheterisation complications 
was assessed. Ocular complications were determined using vision, macular (including Pattern Visual 
Evoked Potentials (PVEPs)), retinal (Electroretinograms (ERG) and ocular motility functions. Efficacy 
(tumour control) was also assessed. 
 
 
Results: All eyes had age appropriate doses of melphalan with five having additional doses of 
topotecan. Severe physiological reactions requiring adrenaline were seen in six patients during the 
catheterisation procedure. Difficulty was documented in accessing the ophthalmic artery in 7/ 27 
catheterisations. The median / mean number of courses of chemotherapy was three. No child had severe 
visual loss as assessed by age appropriate tests (median follow-up 20.9 months range 3.7– 35.2 months). 
One child had nasal choroidal ischemia and a sixth nerve palsy. Post-IAC pVEPs were performed in 
eight and reported as normal. All post-IAC ERGs were normal apart from one (total dose 20mg 
melphalan 0.8mg topotecan). Tumour control was achieved in 6 of 9 cases. 
 
Conclusion: The proportion of visual and ocular motility complications may be reduced by providing 
age adjusted doses of melphalan. Dose rather than complications from catheterisation is the most 
important risk factor for ocular injury.  
 
 
 
 
 
	 	
	
INTRODUCTION 1	
There has been a paradigm shift in the management of retinoblastoma with the acceptance of 2	
chemotherapy being delivered directly to the ophthalmic artery: intra-arterial chemotherapy 3	
(IAC). Many units around the world are using IAC for retinoblastoma1 but the lack of safety 4	
profile data has delayed universal acceptance2-5. Globe salvage without risk of metastases yet 5	
with retained vision would be the goal of any treatment strategy for retinoblastoma. Using 6	
thorough orthoptist assessments, age appropriate visual testing in combination with visual 7	
evoked potentials (VEPs) and electroretinograms (ERGs) on awake children, we have 8	
previously demonstrated that 40% of our earliest cohort developed 3rd nerve palsies5 and 42% 9	
of eyes with healthy foveolae had severe visual loss after intra-arterial melphalan6. We 10	
identified high doses of melphalan, catheterisation complications and previous radiotherapy 11	
as potential risk factors for visual loss and were interested in how modification of these 12	
factors could ameliorate the complications. 13	
 14	
METHODS 15	
This was a retrospective cohort study conducted between January 2013 and December 2015. 16	
Eyes with tumours involving the foveola extending to the foveola were excluded. Approval 17	
for the use of IAC in this study was obtained from the Great Ormond Street Hospital 18	
Children Drugs and Therapeutics Committee and Barts Health Clinical Effectiveness Unit 19	
(#6594) within the tenets of the Declaration of Helsinki. Informed consent was obtained from 20	
the parents or legal guardians, after discussion of the findings, potential risks and benefits of 21	
the procedure. IAC was considered in cases where the tumours failed to respond adequately 22	
to previous treatments or there was a new recurrence not amenable to local therapy (laser, 23	
cryotherapy or plaque therapy). All patients were assessed by MAR or MSS and graded 24	
according to the International Intraocular Retinoblastoma Classification (IIRC)7 and AJCC8. 25	
	 	
	
All patients had received systemic chemotherapy in the form of six cycles of carboplatin, 26	
vincristine and etoposide as first line treatment. Our method of catheterisation of the 27	
ophthalmic artery has been previously reported5, 6. Adrenaline was given following severe 28	
autonomic reactions 9. In addition, we assessed the duration of the procedure and compared 29	
this with our initial cohort6. 30	
We gave age-appropriate doses10, 11 at the time of treatment. For melphalan this resulted in 31	
3mg for 6-12 month olds, 4mg for 1 to 3 year olds and 5 mg above this age. For topotecan, 32	
doses were consistently 0.3 to 0.5 mg for under 3 year olds and 1mg for one child over 3.  All 33	
children had 3 cycles of IAC spaced at 4 weeks. All patients had an examination under 34	
anaesthesia three weeks after each treatment. FFAs were performed in patients after 35	
treatment.  36	
ERGs and VEPs were performed before and after the procedure wherever possible as 37	
previously described6.  Pattern and flash VEPs were recorded according ISCEV standards12  38	
from 3 occipital electrodes; O1,Oz and O2 referred to FpZ. PrVEPs (Pattern reversal VEPs) 39	
were elicited to high contrast checkerboards. Data from the midline Oz were analysed and 40	
reported in this paper.  41	
  As part of our protocol, patients had orthoptic examinations before and three weeks after 42	
each IAC treatment. This included Visual Acuity (VA) assessment, cover testing at near 43	
(1/3m) and distance (6m), ocular motility examination, pupillary assessment and 44	
investigation of binocular vision. Visual acuities were assessed using Cardiff Cards (Fixed 45	
Choice Preferential Looking:FCPL), Keeler Cards (FCPL), Kays picture tests (Optotype), 46	
and Crowded LogMAR, depending upon the age of the child. When possible VA was 47	
assessed uniocularly, otherwise binocular VA was measured. If quantitative assessment was 48	
not possible qualitative methods were used, i.e. fixing and following on a target and whether 49	
there was a fixation preference6.  50
	 	
	
 51	
RESULTS 52	
From January 2013 to December 2015, 23 eyes of 23 patients were treated with IAC in our 53	
department. 14 patients with tumours involving the foveola were excluded. Table 1 lists the 54	
baseline patient and ocular features of the 9 eyes from 9 patients who were recruited into this 55	
study. The median age at the time of the first IAC treatment was 14 months (range 6-125 56	
months). 3 children presented with D eyes according to the IIRC7 and the other 6 eyes had 57	
less advanced disease (Table 1). All patients were alive at last follow-up (median 20.9 58	
months range 3.7– 35.2 months) with no indication of metastases.  59	
Table 1. Summary of patient and ocular features  60	
Feature     Number (%) 
Age (months) Mean (median, 
range) 
 n = 9 
At first IAC   31 (14, 6-125) 
Laterality of retinoblastoma 
 
   
 Bilateral       5 (55.6%) 
 Unilateral  4 (44.4%) 
Affected Fellow eye status 
 
   
 Foveal tumor     1 (11.1%) 
 Extra-foveal 
tumor   
 3 (33.3%) 
 Enucleated  1 (11.1%) 
Affected eye status 
 
Previous 
treatments 
  
  Cryotherapy 5 (55.6%) 
  Laser thermotherapy 7 (77.8%) 
  EBRT 0 
  Plaque 
brachytherapy 
0 
  Systemic 
chemotherapy 
9 (100%) 
Indication for IAM 
 
Edge relapse 
 
  
  Solitary 3 (33.3%) 
  Multiple 5 (55.6%) 
	 	
	
 Vitreous seeding  1 (11.1%) 
International Intraocular Retinoblastoma  
Classification at presentation 
(American Joint Committee on Cancer Staging8) 
   
 A (cT1a)                                          2 (22.2%) 
 B (cT1b)  2 (22.2%) 
 C (cT2a)                                           2 (22.2%) 
 D (cT2b)                                           3 (33.3%) 
 E                                             0 
 61	
 62	
 63	
Treatment 64	
All children had received 6 cycles of systemic chemotherapy (Carboplatin, Etoposide and 65	
Vincristine) prior to IAC. None had received radiation in the form of plaque or external beam 66	
radiation therapy. The indications for treatment included multiple areas of relapse (5 or 55%), 67	
solitary relapse (3) and vitreous seeding (1). All children had age-appropriate doses of 68	
melphalan: 3mg in 3 infants under 12 months, 4 mg in 4 children (aged 1 to 3) and 5 mg in 2 69	
above 3 years of age. Four children had solely intra-arterial melphalan (3-5 mg) and five had 70	
additional topotecan (0.3 to 1 mg). The median dose of melphalan was 4 mg and the median 71	
number of cycles was 3 (range 2-4) as shown in Table 2. 72	
 73	
 74	
 75	
 76	
 77	
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 81	
 82	
Table 2. Visual outcomes and complications following intra-ophthalmic artery melphalan +/- 83	
Topotecan for retinoblastoma: Dose, complications and results. 84	
 85	
Catheter complications 86	
No child suffered from a neurological event following catherisation. Difficulty was found in 87	
seven of 27 catheterisations. Six of nine patients suffered from a severe autonomic episode. 88	
One child (Patient 8) had two uneventful injections of melphalan (5mg) and topotecan (1mg) 89	
yet the third injection into the ophthalmic artery was associated with an autonomic episode 90	
(Table 2). He subsequently developed a temporary sixth nerve palsy and choroidal ischemia. 91	
Learning Curve 92	
Patient 
no 
(age in 
months)  
Dose of 
melphalan 
(number of  IAC 
treatments) 
 
Dose of 
topotecan and 
which treatment 
Catheterisation complications Tumor 
controlled 
at last 
follow up 
Complications Visual acuity 
deterioration 
directly after 
IAC 
1 (6) 3,3,3 mg (3) 0.3mg (1,2,3)  Yes No No 
2 (10) 3,3,4 mg(3) 0.3mg (1,2,3) Autonomic reaction on 2nd injection Yes No No 
3 (12) 4,4,4 mg(3) 0 mg  Autonomic reaction on 2nd injection Yes No No 
4 (24) 4,4 mg(2) 0 mg  Autonomic reaction on 2nd injection No No No 
5 (36) 4,4,5 mg(3) 0 mg  Autonomic reaction on 2nd injection No No No 
6 (14) 4,4,4 mg(3) 0 mg  Initial failed attempt Yes Sluggish pupil No 
7 (125) 5,5,5,5mg(4) 0.4mg (3,4)  No Slight ptosis No 
8 (38) 5,5,5mg(3) 1mg (1,2,3) Autonomic reaction on 3rd injection Yes Yes (nasal 
choroidal 
ischemia and 
VIth nerve 
palsy) 
No 
9 (11) 3,3,3mg(3) 0.5mg (1,2,3) Autonomic reaction on 2nd injection Yes No No 
	 	
	
The average length of time for each procedure was 1 hour 52 minutes (range 1hour 6 minutes 93	
to 3 hours 8 minutes). This compares with our initial cohort6 of 12 patients where the average 94	
duration was 1 hour 32 minutes (range from 1 hour to 2 hours 20 minutes). 95	
Outcome 96	
Tumour control was achieved in 6 eyes (66%) in this group and the other 3 eyes (33%) 97	
eventually went onto enucleation. The 3 eyes that underwent subsequent enucleation 98	
presented with IIRC grades C (1) and D (2) and were assessed for ocular complications of the 99	
treatment prior to enucleation. Of the 6 eyes that avoided enucleation, a partial response was 100	
found in 2, requiring additional treatment to one of the initial tumours and new tumours 101	
respectively. Two other eyes had post-IAC consolidation laser. 102	
Vision 103	
All nine patients had Age Appropriate Normal vision6 (Tables 2 and 3) at the last follow up 104	
(median follow-up 20.9 months range 3.7– 35.2 months). The assessment of infants can be 105	
difficult. Four children were assessed with FCPL, 4 with Optotypes (Kay pictures) and one 106	
was old enough to use crowded LogMAR testing. No child had a deterioration of vision 107	
following IAC. Although 3 eventually had enucleations for progressive disease, none lost 108	
vision prior to surgery.  109	
Ocular Complications 110	
Although no child developed a third nerve palsy, two had a slight ptosis following IAC and 111	
one (Patient 6) had a sluggish pupil (with no motility abnormality nor ptosis) at last follow-112	
up. One child developed a sixth nerve with -4 limitation of abduction directly after the 3rd 113	
cycle of IAC. The same child also developed nasal choroidal ischemia. Visual acuity did not 114	
deteriorate and at last follow-up, he had vision of LogMAR 0.1 with limitation of abduction 115	
	 	
	
of only -0.5. Fundus fluorescein angiograms demonstrated nasal choroidal ischemia in Patient 116	
8  but not in any of the other children. The foveal avascular zone was intact in all children. 117	
Electrodiagnostic Tests (EDTs) 118	
Eight of nine patients had pre-IAC VEPs and ERGs. One child (Patient 5) was unable to be 119	
tested before the IAC was given. Eight of nine patients had post-IAC VEPs (Table 3) 120	
demonstrating good vision. Patient 5 showed an improvement in vision as assessed using 121	
optotypes. All patients had post-IAC ERGs and 8 of 9 showed normal values on testing. The 122	
only patient with a subtle reduction of cone and rod function had a cumulative dose of 20mg 123	
of melphalan and 0.8mg of topotecan. The melphalan dose was the highest in this cohort. 124	
Table 3. Visual outcomes, visually evoked potentials (VEP) and electroretinograms (ERG) 125	
following IAC. 126	
 FUNCTION 
Patient 
(age in 
months) 
VA/VEP 
pre-IAC 
VA/ 
VEP 
post IAC 
 ERGs 
Pre-IAC ERGs Post-IAC 
1 
(6) 
 
Fix and follow 
VEP: good 
LogMar 0.3 FCPL 
VEP: Good 
 
Normal 
 
 
Normal 
 
2 
(10) 
 
LogMAR 0.6 
VEP:ND 
LogMAR 0.2 FCPL 
VEP:Good 
 
ND Normal  
3 
(12) 
 
LogMAR 0.3 
VEP:Good BEO 
 
LogMAR 0.1 Opto 
VEP: Good 
 
Normal 
 
Normal 
 
4 
(24) 
LogMAR 0.1 
VEP: Good 
LogMAR 0.2 FCPL 
VEP: Good 
 
Normal 
 
Normal 
 
5 
(36) 
LogMAR 0.2 
VEP:good 
LogMAR 0.0 Opto 
VEP : ND 
 
 
 
Normal 
 
 
Enucleated ND 
 
6 
(14) 
 
Not F+F 
VEP:Good BEO 
LogMAR 0.8 Opto 
VEP :  Good 
 
Normal 
 
Normal 
 
7 
(125) 
 
LogMAR 0.36 
VEP: Good 
LogMAR 0.24 Log 
VEP: Good Normal  
Subtle reduction rod 
and cone b-waves 
 
8 
(38) 
LogMAR 0.3 
VEP: Good 
LogMAR 0.1 Opto 
VEP: Good 
Normal 
 
Normal 
 
9 
(11) 
LogMAR 0.6 BEO 
 
VEP: Good 
LogMAR 0.48 
BEO FCPL 
VEP: Good 
Normal 
 
Normal 
 
	 	
	
 127	
Abbreviations: 128	
ND: not done 129	
BEO: both eyes open, FCPL: Fixed Choice Preferential Looking, Opto: Optotype ,      130	
F+F: Fixing and Following, Good: Pattern reversal VEPs are evident to 50’ or smaller checks 131	
 132	
DISCUSSION 133	
The use of IAC in eyes with retinoblastoma has gained considerable momentum, with trends 134	
away from enucleation to more attempts at eye-conserving therapy. We have reported on our 135	
early experience of IAC for refractory tumours including complications5 ,visual outcomes6 136	
and pathology findings13. This report aims to quantify the amelioration in side effects and 137	
improvement in visual outcomes.  138	
Efficacy 139	
There is not a direct correlation between dose and complications as not all children who were 140	
given high doses of melphalan in our original visual outcome study lost vision6 : 40% still 141	
retained good vision. Titrating the dose that is efficacious yet is not associated with 142	
complications is difficult. In this work, eight of nine patients had doses of melphalan in 143	
keeping with Gobin et al’s work10 but we note that the authors had advised a reduction in 144	
dose if systemic chemotherapy had been given prior to treatment. We did not reduce our IAC 145	
melphalan dose.  146	
A child with a C eye (patient 7) had multiple vitreous seeds following systemic 147	
chemotherapy and would have been treated with intravitreal chemotherapy now rather than 148	
IAC in 2013. That child went on to have an enucleation. Two thirds of patients (6 of 9) with 149	
refractory retinoblastoma avoided enucleation using lower doses of melphalan (compared to 150	
our earlier cohort)  and this compares with success rates of 50 to 67% that have previously 151	
been reported4, 10, 14. Peterson14 and colleagues only treated Group D eyes and found that 7.5 152	
mg was effective in salvaging the globe in 5 children (ages 6 months to 7 years). Group D 153	
	 	
	
eyes often have poor visual potential and choroidal ischemia is a valid sacrifice to avoid 154	
enucleation. The patients in our cohort all had visual potential and we were keen to avoid 155	
iatrogenic visual loss. It is felt that children who have choroidal ischemia are unlikely to 156	
relapse due to the high concentration of drug in the choroidal vascular bed. The only child to 157	
have choroidal ischemia in this cohort was fortunate that the ischemia was located nasally 158	
and therefore did not affect his visual acuity.  159	
Learning Curve 160	
A potential cause for the reduction of complications may be attributed to a learning curve. A 161	
surrogate for experience that we were able to measure is length of time for the procedure. The 162	
first cohort6 involved 12 patients from the first 20 who had IAC. The recent cohort was 163	
treated after at least 35 patients had undergone treatment. We were surprised to find that the 164	
average length of time of the procedure had actually increased over time. As there were 165	
complications during catheter insertion in both cohorts, we felt that the learning curve may 166	
play a part but is unlikely to be sole cause for the ocular and cranial nerve complications. 167	
Catheter position 168	
We used the small and flexible 1.2F microcatheter (Balt, Montmorency, France Extrusion), 169	
either lodged at the ostium or tracked over a wire into the ophthalmic artery proper if ostial 170	
stability cannot be achieved. The ophthalmic artery was catheterised in a stable, non-wedged 171	
position to ensure antegrade flow of chemotherapy whilst maintaining angiographic perfusion 172	
of the choroid. Injection of chemotherapeutic agents only took place if angiography 173	
demonstrated antegrade flow around the catheter and a visible choroidal blush was seen. 174	
Many units use larger catheters10, 14, 15 which are more likely to cause a wedge effect if 175	
inserted into the ophthalmic artery.  176	
One patient (#8) developed complications following an autonomic reaction9 and it is difficult 177	
to state if the reaction caused the complications as 5 other patients had a reaction without 178	
	 	
	
consequence. This is the second case of a sixth nerve palsy15 to be described in the literature 179	
with the first case involving a 4F catheter with 5mg of Melphalan in a 3 year old.  180	
Toxicity 181	
No child suffered severe visual loss and one child (11%) developed a cranial nerve palsy and 182	
choroidal ischemia. This study provides reassurance to units that may consider using IAC in 183	
patients with age appropriate vision. Munier and colleagues3 reported final visual acuities, 184	
but did not report the proportion of eyes starting with good visual potential. We have 185	
previously demonstrated that 42% of children suffer severe visual loss6. It is reassuring that 186	
with lower doses of IAC melphalan, normal ERGs were noted in nearly all patients. A 187	
deterioration of photopic response has been correlated with improved outcomes16 and a 188	
potential association of 14 mg of melphalan has been associated with ERG deterioration17. 189	
The one child had a subtle ERG deterioration and had a cumulative dose of melphalan of 190	
20mg pointing to dose as being an important factor. One child had choroidal ischemia yet the 191	
ERG was normal demonstrating a large area of functioning retina was present.  192	
The innovative approach of age appropriate visual testing in infants and children with 193	
retinoblastoma and awake electrodiagnostic studies including VEPs have enabled us to assess 194	
a treatment modality and modify risk factors to determine the cause of complications. The 195	
necessarily small sample size reflects the patients with normal visual potential. In addition, 196	
there is a mixture of melphalan and topotecan given in some patients and it is reassuring that 197	
there was no summative damage to the retina as demonstrated on electrophysiology. 198	
CONCLUSIONS 199	
It is essential with new treatments to inform families of potential complications and modify 200	
iatrogenic risk factors. A recent review2 of IAC has emphasized the lack of visual outcome 201	
data. By analyzing a subset of patients, we have shown that an age adjusted dose of 202	
melphalan is associated with reduced toxicity and excellent salvage rates.  203	
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